Article info
Clinical pharmacy
CP-169 Effectiveness of biosimilar filgrastim vs original granulocyte-colony stimulating factor (G-CSF) in febrile neutropenia prevention in breast cancer patients receiving docetaxel/doxorubicin/cyclophosphamide (TAC)
Citation
CP-169 Effectiveness of biosimilar filgrastim vs original granulocyte-colony stimulating factor (G-CSF) in febrile neutropenia prevention in breast cancer patients receiving docetaxel/doxorubicin/cyclophosphamide (TAC)
Publication history
- First published February 14, 2016.
Online issue publication
February 14, 2016
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© 2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions